BRIEF—Recordati acquires rights to Cystagon from Mylan

Italian drugmaker Recordati has completed an agreement with Mylan for the acquisition of the rights to Cystagon (cysteamine bitartrate), indicated for the treatment of proven nephropathic cystinosis in children and adults, for certain territories, including Europe.

The product was previously commercialized by Orphan Europe (a Recordati group company) under license from Mylan.

"We are very satisfied with the agreement reached with Mylan for the acquisition of the rights to Cystagon," stated Andrea Recordati, chief executive and vice chairman.

"Our rare disease company Orphan Europe has, over the years, successfully made this product available to patients suffering from nephropathic cystinosis in Europe and in many other parts of the world. The definitive acquisition of the rights enables us to continue offering this life-saving treatment to patients," he added.